



Prior Authorization Request

TAFINLAR (dabrafenib)

Instructions

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

Part A – Patient

Patient information

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:	Province:	Postal Code:	
Email address:			
Telephone (home):	Telephone (cell):	Telephone (work):	

Coordination of benefits

Patient Assistance Program	Is the patient enrolled in any patient assistance program? <input type="checkbox"/> Yes <input type="checkbox"/> No Contact Name: _____ Fax: _____
Provincial Coverage	Has the patient applied for reimbursement under a provincial plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>
Primary Coverage	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>

Authorization

On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

Plan Member Signature

Date



Prior Authorization Request

TAFINLAR (dabrafenib)

Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do not provide genetic test information or results.

SECTION 1 – DRUG REQUESTED

TAFINLAR (dabrafenib)		<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request*
Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
Site of drug administration:			
<input type="checkbox"/> Home	<input type="checkbox"/> Physician's office/Infusion clinic	<input type="checkbox"/> Hospital (outpatient)	<input type="checkbox"/> Hospital (inpatient)

* Please submit proof of prior coverage if available

SECTION 2 – ELIGIBILITY CRITERIA

1. Please indicate if the patient satisfies the below criteria:

Melanoma – Unresectable or Metastatic

- For the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in an adult, AND
- TAFINLAR will be used as monotherapy and the patient has not been treated with BRAF or mitogen-activated protein kinase kinase (MEK) inhibitors, OR
- TAFINLAR will be used in combination with MEKINIST (trametinib) and the patient has not previously progressed on a BRAF inhibitor

Melanoma – Resectable, Adjuvant

- For the adjuvant treatment of melanoma with a BRAF V600 mutation and involvement of lymph node(s), following complete resection in an adult, AND
- TAFINLAR will be used in combination with MEKINIST (trametinib)

Non-Small Cell Lung Cancer

- For the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation in an adult, AND
- TAFINLAR will be used in combination with MEKINIST (trametinib)

Low-Grade Glioma

- For the treatment of low-grade glioma (LGG) with a BRAF V600E mutation, AND
- The patient is 1 year of age or older, AND
- The patient has not received prior systemic therapy, AND
- TAFINLAR will be used in combination with MEKINIST (trametinib)



Prior Authorization Request

TAFINLAR (dabrafenib)

High-Grade Glioma

- For the treatment of high-grade glioma (HGG) with a BRAF V600E mutation, AND
- The patient is 1 year of age or older, AND
- The patient has relapsed, progressed, or failed to respond to radiation or chemotherapy (*Please list prior therapies in the chart below*), AND
- TAFINLAR will be used in combination with MEKINIST (trametinib)

OR

- None of the above criteria applies.

Relevant additional information:

2. Please list previously tried therapies

Drug	Dosage and administration	Duration of therapy		Reason for cessation	
		From	To	Inadequate response	Allergy/ Intolerance
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>

SECTION 3 – PRESCRIBER INFORMATION

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

Please fax or mail the completed form to Express Scripts Canada®

Fax: Express Scripts Canada Clinical Services
1 (855) 712-6329

Mail: Express Scripts Canada Clinical Services
6985 Financial Drive, Suite 300
Mississauga, ON, L5N 0G3